We are live on
!
Find out more
KAM
Krensavage Asset Management Portfolio holdings
AUM
$256M
1-Year Est. Return
69.63%
This Fund
S&P 500
This Quarter
Est. Return
-3.86%
1 Year Est. Return
+69.63%
3 Year Est. Return
+113.28%
5 Year Est. Return
+196.5%
10 Year Est. Return
+463.27%
AUM
$311M
AUM Growth
+$17.9M
(+6.1%)
Cap. Flow
+$37.9M
Cap. Flow
% of AUM
12.19%
Top 10 Holdings %
Top 10 Hldgs %
95.85%
Holding
13
New
1
Increased
9
Reduced
3
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$14.6M |
| 2 |
Enanta Pharmaceuticals
ENTA
|
+$11.2M |
| 3 |
TARO
Taro Pharmaceutical Industries Ltd.
TARO
|
+$10.9M |
| 4 |
United Therapeutics
UTHR
|
+$7.48M |
| 5 |
Alkermes
ALKS
|
+$4.69M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$7.26M |
| 2 |
McKesson
MCK
|
+$5.28M |
| 3 |
Gilead Sciences
GILD
|
+$284K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.87% |
| 2 | Technology | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
United Therapeutics
UTHR
$25.8B
| $51.2M | 16.46% |
539,646
+78,702
| +17% | +$7.48M |
|
|
2
Regeneron Pharmaceuticals
REGN
$78.5B
| $42.4M | 13.64% |
86,817
-17,603
| -17% | -$7.26M |
|
|
ALXN
3
DELISTED
Alexion Pharmaceuticals
ALXN
| $41.5M | 13.35% |
462,138
+148,582
| +47% | +$14.6M |
|
|
4
Enanta Pharmaceuticals
ENTA
$366M
| $36M | 11.58% |
700,318
+210,933
| +43% | +$11.2M |
|
5
Biogen
BIIB
$30B
| $35M | 11.27% |
110,771
+867
| +0.8% | +$263K |
|
|
TARO
6
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
| $29.8M | 9.59% |
487,275
+147,456
| +43% | +$10.9M |
|
|
7
McKesson
MCK
$100B
| $29.5M | 9.5% |
218,306
-36,024
| -14% | -$5.28M |
|
|
8
Alkermes
ALKS
$8.22B
| $16.8M | 5.42% |
1,167,631
+262,553
| +29% | +$4.69M |
|
|
9
Gilead Sciences
GILD
$162B
| $8.8M | 2.83% |
117,755
-4,106
| -3% | -$284K |
|
|
SRGA
10
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
| $6.89M | 2.22% |
134,259
+13,294
| +11% | +$1.39M |
|
|
IVC
11
DELISTED
Invacare Corporation
IVC
| $6.59M | 2.12% |
887,246
+6,844
| +0.8% | +$53K |
|
12
AnaptysBio
ANAB
$1.58B
| $6.27M | 2.02% |
443,877
+3,468
| +0.8% | +$52.6K |
|
|
CHNG
13
DELISTED
Change Healthcare Inc. Common Stock
CHNG
| $36K | 0.01% |
+3,639
| New | +$50.9K |
|
Similar funds
CIA
2
CIM
JFG
PIP
LRIC
GAMC
TIA
Krensavage Asset Management's Q1 2020 Portfolio in Review
As of Q1 2020, Krensavage Asset Management held 13 positions worth $311M, up 6.1% from $293M the previous quarter. Its ten largest holdings account for 96% of the portfolio.
Krensavage Asset Management deployed $37.9M of net new capital in Q1 2020, opening 1 new position and adding to 9 existing holdings. Its largest new stake was Change Healthcare Inc. Common Stock: 3,639 shares worth $36K.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Technology.
On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $7.26M trimmed.
- Krensavage Asset Management's largest Q1 2020 buy was Change Healthcare Inc. Common Stock: 3,639 shares worth $36K.
- Krensavage Asset Management added most to Alexion Pharmaceuticals in Q1 2020, an estimated $14.6M increase.
- Krensavage Asset Management's biggest Q1 2020 reduction was Regeneron Pharmaceuticals, cutting an estimated $7.26M.
- Krensavage Asset Management's ten largest holdings make up 96% of its $311M portfolio in Q1 2020.
- Krensavage Asset Management opened 1 new position and closed 0 in Q1 2020.
- Krensavage Asset Management's portfolio value rose 6.1% quarter-over-quarter to $311M.
Based on Krensavage Asset Management's 13F filing for Q1 2020, filed 18 May 2020.